Tesio, Cerela D.
HRN: 24-37-88 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/11/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
01/11/2024
01/17/2024
IVT
500mg
Q8
E. Histolytica Infection
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes